PHI FPX 3200 Assessment 2 A Right to Experimental Drugs?

Student Name

Capella University

PHI FPX 3200 Ethics in Health Care

Prof. Name

Date

A Right to Experimental Drugs

The right to experimental drugs is an ethical and legal issue involving patient autonomy, medical research, safety, informed consent, and access to potentially life-saving treatments. Patients with serious or life-threatening conditions who have exhausted approved treatment options may seek access to investigational drugs. Supporters argue that expanded access can provide additional treatment opportunities when conventional options are unavailable, while critics emphasize that experimental drugs may have uncertain benefits and unknown or insufficiently studied risks (Bunnik & Aarts, 2019; Feustel et al., 2019).

In the United States, the Food and Drug Administration (FDA) regulates drugs and evaluates evidence concerning their safety and effectiveness. This creates an important tension between providing patients with access to investigational treatments and protecting them from treatments whose benefits and risks have not been adequately established (U.S. Food and Drug Administration [FDA], n.d.). Ethical decision-making therefore requires careful consideration of the available evidence, patient preferences, potential benefits, possible harms, and regulatory requirements.

Ethical Theories and Moral Principles in Healthcare

Ethical theories provide frameworks that healthcare professionals can use when addressing difficult decisions involving patients, treatments, and medical research. Several ethical approaches are particularly relevant to decisions about experimental drugs.

Utilitarianism evaluates an action according to its consequences, generally emphasizing outcomes that maximize overall well-being. In the context of experimental drugs, a utilitarian analysis may consider whether providing access could produce meaningful benefits for an individual patient or contribute to broader medical knowledge (Tseng & Wang, 2021; Vearrier & Henderson, 2021).

Deontological ethics focuses on duties, rules, and moral obligations rather than primarily on outcomes. From this perspective, healthcare professionals may have obligations to respect patient autonomy, provide accurate information, and avoid exposing patients to unreasonable harm.

Virtue ethics focuses on moral character and qualities such as compassion, honesty, responsibility, and empathy. In decisions involving investigational treatments, a virtue-based approach can encourage healthcare professionals to consider how these qualities should guide communication and patient care.

Healthcare ethics also relies on four widely recognized principles:

• Autonomy: Respecting a patient’s right to make informed healthcare decisions.
• Beneficence: Acting for the patient’s benefit.
• Nonmaleficence: Avoiding or minimizing preventable harm.
• Justice: Promoting fairness in the distribution of healthcare resources and opportunities.

These principles may sometimes conflict. For example, respecting a patient’s desire to try an experimental treatment may support autonomy, while concerns about unknown risks may support nonmaleficence. Ethical decision-making requires these competing considerations to be examined rather than assuming that one principle will always determine the outcome (Varkey, 2021).

Why Informed Consent Matters for Experimental Drugs

Informed consent is particularly important when patients are considering experimental or investigational treatments. Unlike approved medications, investigational drugs may have limited evidence regarding their effectiveness, appropriate dosage, side effects, or long-term outcomes.

Informed consent involves providing patients with understandable information about the proposed treatment so they can make a voluntary decision. This includes discussing the known and potential risks, possible benefits, available alternatives, and uncertainties surrounding the treatment (Dankar et al., 2019).

For experimental drugs, the consent process should address:

• The investigational nature of the treatment.
• Known and potential risks and side effects.
• The evidence currently available about effectiveness.
• Alternative treatment options.
• The possibility that the treatment may not provide a benefit.
• The patient’s ability to withdraw from participation when applicable.

Informed consent is more than obtaining a signature on a document. It is an ongoing communication process that allows patients to ask questions and make decisions based on their understanding of the available information. Patients should also be able to make their decisions voluntarily, without coercion or inappropriate pressure (Dankar et al., 2019; Varkey, 2021).

Assumptions Underlying Informed Consent

Several important assumptions support the informed-consent process in experimental treatment decisions. First, patients should be treated as autonomous individuals capable of participating in decisions about their healthcare. Second, healthcare professionals have a responsibility to communicate relevant information accurately and understandably.

The process also assumes that patients have an opportunity to comprehend the information provided and that their decision is voluntary. Because knowledge about an experimental drug can change as research progresses, consent may also need to be revisited when meaningful new information becomes available.

These assumptions help protect patient dignity while supporting ethical participation in clinical research and access to investigational treatments.

Potential Benefits of Unapproved Experimental Drugs

Access to an unapproved experimental drug may offer an additional option to patients with serious conditions who have limited or no satisfactory approved treatments. For some patients, participation in clinical research or an expanded-access pathway may provide an opportunity to receive an investigational therapy while contributing information that could benefit future patients.

Research on expanded access has also shown that patients with serious illnesses may value opportunities to explore investigational treatments when conventional options have been exhausted (Bunnik & Aarts, 2019). However, the existence of an investigational treatment does not establish that it will be effective for a particular patient.

Another potential benefit is the generation of additional evidence about a treatment. Information obtained through appropriate clinical research can contribute to understanding the drug’s safety, effectiveness, and potential applications.

Risks and Ethical Concerns of Experimental Drugs

Experimental drugs also present significant uncertainties. A treatment may not have completed the clinical studies normally required to establish its safety and effectiveness. As a result, patients may face risks that are not yet fully understood.

Potential concerns include unexpected adverse effects, ineffective treatment, interactions with other therapies, and uncertainty about long-term outcomes. Research examining unapproved treatments has emphasized the importance of carefully evaluating both potential benefits and risks before exposing patients to investigational therapies (Feustel et al., 2019).

There are also ethical concerns surrounding informed consent. Patients facing serious illnesses may feel pressure to pursue any available treatment, making it particularly important that healthcare professionals communicate uncertainty honestly and avoid creating unrealistic expectations.

Should Unapproved Experimental Drugs Be Offered to Patients?

There is no single ethical principle that resolves every case involving an experimental drug. The decision may depend on the patient’s medical circumstances, the seriousness of the condition, the available evidence, potential alternatives, and the regulatory pathway through which the treatment could be accessed.

Supporters of expanded access generally emphasize patient autonomy and the possibility of obtaining a treatment when conventional options have been exhausted. Critics emphasize patient protection, scientific evidence, and the possibility that an unproven treatment could cause harm or delay more appropriate care.

A case-by-case approach can therefore involve examining the available evidence, discussing uncertainties with the patient, considering alternatives, and following applicable regulatory and professional requirements.

Using Approved Drugs for Different Patient Populations

Another related issue concerns the use of an approved drug outside the population or indication for which it was originally evaluated. Regulatory approval generally applies to particular conditions, populations, dosages, formulations, or other specified uses. Evidence supporting one use does not automatically establish safety and effectiveness for every other condition or patient population.

Using a medication in a different clinical context may sometimes be considered by healthcare professionals when supported by appropriate evidence and clinical judgment. However, this practice requires careful consideration because patient characteristics, disease mechanisms, dosage requirements, and treatment responses can differ.

Expanding medication use without sufficient evidence may expose patients to unnecessary risks. It can also contribute to inappropriate medication use and healthcare resource utilization. Therefore, healthcare professionals need to evaluate the available evidence rather than assuming that approval for one indication establishes effectiveness for another.

Ethical Considerations When Expanding Drug Use

The ethical principles of autonomy, beneficence, nonmaleficence, and justice remain relevant when considering medications outside their original approved uses.

Autonomy requires patients to receive appropriate information so they can participate in treatment decisions. Beneficence requires consideration of whether the proposed treatment could reasonably benefit the patient. Nonmaleficence requires attention to potential harms, while justice raises questions about equitable access and appropriate use of healthcare resources (Varkey, 2021).

A balanced approach should therefore consider both the individual patient’s circumstances and the quality of evidence supporting the proposed treatment.

Knowledge Gaps and Areas for Further Research

Important questions remain regarding investigational and expanded-access treatments. Additional research can help clarify how experimental or previously approved medications perform in patient populations different from those included in their original studies.

Further evidence is particularly valuable in several areas:

• Long-term safety and effectiveness.
• Outcomes among different patient populations.
• Potential adverse effects and drug interactions.
• Ethical approaches to expanded access.
• Patient understanding of treatment uncertainty.
• Appropriate standards for informed consent.
• Effects of broader medication use on healthcare resources.

Research in these areas can help healthcare professionals, regulators, researchers, and patients make better-informed decisions.

Conclusion

The right to experimental drugs involves a difficult balance between patient autonomy, potential therapeutic benefits, medical uncertainty, and patient safety. Experimental treatments may provide an important option for people who have exhausted approved therapies, but their uncertain risks and effectiveness require careful evaluation.

Ethical principles such as autonomy, beneficence, nonmaleficence, and justice provide useful frameworks for analyzing these decisions. Informed consent is particularly important because patients must understand what is known, what remains uncertain, and what alternatives may be available.

Ultimately, decisions involving experimental drugs should be based on the available scientific evidence, the patient’s individual circumstances and preferences, appropriate informed-consent procedures, and applicable regulatory requirements. Continued research is essential for reducing knowledge gaps and improving ethical decision-making surrounding investigational treatments.

References

Amrutkar, S. S., Patil, S. B., & Mundada, A. S. (2022). Abbreviated new drug submission approval process: An overview. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. https://doi.org/10.1177/17411343221146094

Bendicksen, L., Kesselheim, A. S., & Rome, B. N. (2022). The vexing voyage of vasopressin. Chest, 162(2), 433–435. https://doi.org/10.1016/j.chest.2022.02.048

Borysowski, J., & Górski, A. (2019). Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. European Journal of Internal Medicine, 65, 12–16. https://doi.org/10.1016/j.ejim.2019.04.008

Bunnik, E. M., & Aarts, N. (2019). What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Medical Ethics, 20, Article 31. https://doi.org/10.1186/s12910-019-0420-8

Cohen, P. A., Avula, B., Wang, Y. H., Zakharevich, I., & Khan, I. (2020). Five unapproved drugs found in cognitive enhancement supplements. Neurology: Clinical Practice. https://doi.org/10.1212/CPJ.0000000000000960

Dankar, F. K., Gergely, M., & Dankar, S. K. (2019). Informed consent in biomedical research. Computational and Structural Biotechnology Journal, 17, 463–474. https://doi.org/10.1016/j.csbj.2019.03.010

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs?

Feustel, A. C., MacPherson, A., Fergusson, D. A., Kieburtz, K., & Kimmelman, J. (2019). Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology, 94(1), e1–e14. https://doi.org/10.1212/WNL.0000000000008699

Heydari, M., Mehraeen, M., & Joulaei, H. (2020). Over medication and waste of resources in physicians’ prescriptions: A cross-sectional study in southwestern Iran. Shiraz E-Medical Journal, 21(9). https://doi.org/10.5812/semj.97662

Madeddu, C., Neri, M., Sanna, E., Oppi, S., & Macciò, A. (2021). Experimental drugs for chemotherapy- and cancer-related anemia. Journal of Experimental Pharmacology, 13, 593–611. https://doi.org/10.2147/JEP.S262349

Nandifa, V. N. P., Jena, Y., & Joewana, S. (2020). Beneficence is the highest moral imperative of a doctor dealing with the poor quality of patient autonomy. Jurnal Pendidikan Kedokteran Indonesia: The Indonesian Journal of Medical Education, 9(1), 44. https://doi.org/10.22146/jpki.44511

O’Mathúna, D. P., Escartín, C. P., Roche, P., & Marlowe, J. (2020). Engaging citizen translators in disasters. Translation and Interpreting Studies. https://doi.org/10.1075/tis.20003.oma

Quaranta, A., D’Isidoro, O., Piattelli, A., Hui, W. L., & Perrotti, V. (2022). Illegal drugs and periodontal conditions. Periodontology 2000, 90(1), 62–87. https://doi.org/10.1111/prd.12450

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs?

Tseng, P.-E., & Wang, Y.-H. (2021). Deontological or utilitarian? An eternal ethical dilemma in outbreak. International Journal of Environmental Research and Public Health, 18(16), 8565. https://doi.org/10.3390/ijerph18168565

U.S. Food and Drug Administration. (n.d.). Drugs. https://www.fda.gov/drugs

Varkey, B. (2021). Principles of clinical ethics and their application to practice. Medical Principles and Practice, 30(1), 17–28. https://doi.org/10.1159/000509119

Vearrier, L., & Henderson, C. M. (2021). Utilitarian principlism as a framework for crisis healthcare ethics. HEC Forum, 33(1), 45–60. https://doi.org/10.1007/s10730-020-09431-7

White, C. M. (2022). Continued risk of dietary supplements adulterated with approved and unapproved drugs: Assessment of the U.S. Food and Drug Administration’s tainted supplements database 2007 through 2021. The Journal of Clinical Pharmacology, 62(8), 928–934. https://doi.org/10.1002/jcph.2046